Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic Cells In Vivo

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Ciré, Séverine ^a,b,c   Rocha, Sylvie Da ^a,b,c   Yao, Roseline ^a,b,c   Fisson, Sylvain ^a,b,c   Buchholz, Christian J ^d   Collins, Mary K ^e   Galy, Anne ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^c Molecular Biotechnology and Gene Therapy Paul Ehrlich Institut ^*

^d PAUL EHRLICH INSTITUT   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA; GLYCOPROTEIN P 15095; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSGENE; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; C57BL MOUSE; CELLULAR IMMUNITY; CYTOLOGY; DRUG EFFECTS; GENE; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LENTIVIRINAE; TH1 TH2 BALANCE;

ANIMALS; ANTIGENS, CD11C; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENE EXPRESSION; GENES, MHC CLASS II; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAVENOUS; LENTIVIRUS; MICE; MICE, INBRED C57BL; TH1-TH2 BALANCE; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84904815108     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101644     Document Type: Article

References (25)

1. Hu B, Tai A, Wang P (2011) Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 239: 45-61.
2. Di Nunzio F, Felix T, Arhel NJ, Nisole S, Charneau P, et al. (2012) HIV-derived vectors for therapy and vaccination against HIV. Vaccine 30: 2499-2509.
3. Kreutz M, Tacken PJ, Figdor CG (2013) Targeting dendritic cells - why bother? Blood 121: 2836-2844.
4. Yang L, Yang H, Rideout K, Cho T, Joo KI, et al. (2008) Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 26: 326-334. (Pubitemid 351355129)
5. Goyvaerts C, De Groeve K, Dingemans J, Van Lint S, Robays L, et al. (2012) Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 19: 1133-1140.
6. Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, et al. (2010) Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7: 929-935.
7. Ageichik A, Buchholz CJ, Collins MK (2011) Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 22: 1249-1254.
8. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK (2009) Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther 20: 554-562.
9. Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, et al. (2005) A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 12: 597-606. (Pubitemid 40468107)
10. Boisgerault F, Gross DA, Ferrand M, Poupiot J, Darocha S, et al. (2013) Prolonged gene expression in muscle is achieved without active immune tolerance using microRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther.
11. Funke S, Maisner A, Muhlebach MD, Koehl U, Grez M, et al. (2008) Targeted cell entry of lentiviral vectors. Mol Ther 16: 1427-1436.
12. Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, et al. (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22: 343-356.
13. Sudres M, Cire S, Vasseur V, Brault L, Da Rocha S, et al. (2012) MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther 20: 1571-1581.
14. Abel T, El Filali E, Waern J, Schneider IC, Yuan Q, et al. (2013) Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood 122: 2030-2038.
15. VandenDriessche T, Thorrez L, Naldini L, Follenzi A, Moons L, et al. (2002) Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100: 813-822. (Pubitemid 34832606)
16. Goyvaerts C, Dingemans J, De Groeve K, Heirman C, Van Gulck E, et al. (2013) Targeting of human antigen-presenting cell subsets. J Virol.
17. Goyvaerts C, Kurt DG, Van Lint S, Heirman C, Van Ginderachter JA, et al. (2014) Immunogenicity of targeted lentivectors. Oncotarget.
18. Kneissl S, Zhou Q, Schwenkert M, Cosset FL, Verhoeyen E, et al. (2013) CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PLoS One 8: e79047.
19. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M (2013) LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110: 7306-7311.
20. Amirache F, Levy C, Costa C, Mangeot PE, Torbett BE, et al. (2014) Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 123: 1422-1424.
21. Garcia-Vallejo JJ, van Kooyk Y (2013) The physiological role of DC-SIGN: A tale of mice and men. Trends Immunol.
22. Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, et al. (2010) HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J Virol 84: 5627-5636.
23. Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, et al. (2009) Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. Immunity 31: 209-219.
24. Knight S, Collins M, Takeuchi Y (2013) Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr Gene Ther 13: 211-227.
25. Buchholz CJ, Muhlebach MD, Cichutek K (2009) Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol 27: 259-265.